Jule Taubmann

Erlangen, BY, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial.

CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial.

Journal: Nature medicine

Published: September 30, 2025

Effects of CD19 CAR T Cell Therapy on Quality of Life and Direct Healthcare Costs in Systemic Lupus Erythematosus: A Preliminary Analysis.

Effects of CD19 CAR T Cell Therapy on Quality of Life and Direct Healthcare Costs in Systemic Lupus Erythematosus: A Preliminary Analysis.

Journal: The Journal of rheumatology

Published: September 04, 2025

Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with refractory systemic lupus erythematosus - Authors' reply.

Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with refractory systemic lupus erythematosus - Authors' reply.

Journal: The Lancet. Rheumatology

Published: July 23, 2025

Long-term follow up of efficiency and safety of CD19-CAR T-cell treatment of systemic lupus erythematosus

Long-term follow up of efficiency and safety of CD19-CAR T-cell treatment of systemic lupus erythematosus

Journal: Zeitschrift fur Rheumatologie

Published: July 18, 2025

Effects of different B-cell-depleting strategies on the lymphatic tissue.

Effects of different B-cell-depleting strategies on the lymphatic tissue.

Journal: Annals of the rheumatic diseases

Published: March 25, 2025

Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study.

Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study.

Journal: The Lancet. Rheumatology

Published: February 19, 2025

BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells.

BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells.

Journal: Nature medicine

Published: January 11, 2025

Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma.

Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma.

Journal: Blood

Published: January 09, 2025

Exploring CAR T-Cell Dynamics: Balancing Potent Cytotoxicity and Controlled Inflammation in CAR T-Cells Derived from Systemic Sclerosis and Myositis Patients.

Exploring CAR T-Cell Dynamics: Balancing Potent Cytotoxicity and Controlled Inflammation in CAR T-Cells Derived from Systemic Sclerosis and Myositis Patients.

Journal: International journal of molecular sciences

Published: November 28, 2024

Real-World-Evidence of Digital Health Applications (DiGAs) in Rheumatology: Insights from the DiGAReal Registry.

Real-World-Evidence of Digital Health Applications (DiGAs) in Rheumatology: Insights from the DiGAReal Registry.

Journal: Rheumatology and therapy

Published: November 10, 2024

Advancements and challenges in CAR T cell therapy in autoimmune diseases.

Advancements and challenges in CAR T cell therapy in autoimmune diseases.

Journal: Nature reviews. Rheumatology

Published: June 28, 2024

CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series.

CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series.

Journal: The Lancet. Rheumatology

Published: May 07, 2024

Showing 1-12 of 26

Last Updated: 09/26/2026